

development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. *J Viral Hepat* 1997;4 Suppl 2:79-82. ID:9429213

12. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. *European Concerted Action on Viral Hepatitis (EUROHEP)*. *Hepatology* 1997;26:1338-42.

## 原因療法（アルコール自己免疫他）

### 27. アルコール性肝硬変では禁酒により線維化が改善するか

1. Campbell S, Timms PM, Maxwell PR, Doherty EM, Rahman MZ, Lean ME, Danesh BJ: Effect of alcohol withdrawal on liver transaminase levels and markers of liver fibrosis. *J Gastroenterol Hepatol* 2001;16:1254-9.
2. Urashima S, Tsutsumi M, Ozaki K, Tsuchishima M, Shimanaka K, Ueshima Y, Takase S: Immunohistochemical study of hyaluronate receptor (CD44) in alcoholic liver disease. *Alcohol Clin Exp Res* 2000;24:34S-38S.
3. Urashima S, Tsutsumi M, Shimanaka K, Ueshima Y, Tsuchishima M, Itoh T, Kawahara H, Takase S: Histochemical study of hyaluronate in alcoholic liver disease. *Alcohol Clin Exp Res* 1999;23:56S-60S.
4. Tsutsumi M, Sawada M, Takase S, Chen WB, Ueshima Y, Tsuchishima M, Shimanaka K, Itoh T, Kawahara H: Clinical significance of hepatitis GB virus C infection in alcoholic liver disease. *Alcohol Clin Exp Res* 1997;21:1722-5.
5. Jmelnitzky AC: [New suggestions for the management of alcoholic liver diseases] *Acta Gastroenterol Latinoam* 1995;25:73-84.
6. Silva G, Fluxa F, Bresky G, Backhouse C, Palma M, Ruiz M, Hirsch S, Iturriaga H: Splanchnic and systemic hemodynamics in early abstinence and after ethanol administration in non-cirrhotic alcoholic patients. *J Hepatol* 1994;20:494-9.
7. Sherman DI, Williams R: Liver damage: mechanisms and management. *Br Med Bull* 1994;50:124-38.
8. Kato K, Nishimura D, Sano H, Katada N, Sugimoto Y, Noba H, Yoshino M, Samori T, Mitani Y, Takeichi M: [Long-term follow-up study of alcoholic liver disease] *Nippon Shokakibyo Gakkai Zasshi* 1990;87:1829-36.
9. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J: Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. *J Hepatol* 1986;2:33-42.
10. Kremer A, Rios B, Bruno M, Heinrichs G: [Use of medroxyprogesterone in human hepatic cirrhosis] *Acta Gastroenterol Latinoam* 1985;15:25-31.

### 28. アルコール性肝硬変では禁酒により肝硬変の進展が抑制されるか

1. Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, Santos PM, Alves MM, Moura MC: Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. *Eur J Gastroenterol Hepatol* 2002;14:377-81.
2. Galambos JT, Riepe SP: Use of colchicine and steroids in the treatment of alcoholic liver disease. *Recent Dev Alcohol* 1984;2:181-94.

### 29. AIHに対して副腎皮質ホルモンを投与すると線維化が改善するか

1. Ostojic R: [Autoimmune hepatitis] *Acta Med Croatica* 2003;57:201-5.
2. Luxon BA: Autoimmune hepatitis. Making sense of all those antibodies. *Postgrad Med* 2003;114:79-82, 85-8.
3. Czaja AJ, Carpenter HA: Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. *Liver Int* 2003;23:116-23.
4. Heneghan MA, McFarlane IG: Current and novel immunosuppressive therapy for autoimmune hepatitis. *Hepatology* 2002;35:7-13.
5. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW: Long-term management and prognosis of

- autoimmune hepatitis (AIH): a single center experience. *Z Gastroenterol* 2001;39:339-41, 344-8.
6. Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. *J Clin Gastroenterol* 2001;32:428-30.
  7. Czaja AJ, Carpenter HA, Lindor KD: Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. *Hepatology* 1999;30:1381-6.
  8. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R: Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *Hepatology* 1998;28:296-301.
  9. Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML: An atypical presentation for primary sclerosing cholangitis. *Dig Dis Sci* 1997;42:2009-16.

### 30. AIHによる肝硬変にステロイドを投与すると予後は改善するか

1. Jain A, Pokharna R, Eghtesad B, Potdar S, Kashyap R, Kingery L, Fung J: Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival. *Transplant Proc* 2002;34:1524-5.
2. Roberts SK, Therneau TM, Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. *Gastroenterology* 1996;110:848-57.
3. Renner EL: [Treatment of autoimmune chronic active hepatitis and of primary biliary cirrhosis] *Schweiz Med Wochenschr* 1994;124:495-501.
4. Michel H, Blanc P: [Cirrhosis secondary to chronic autoimmune hepatitis] *Rev Prat* 1991;41:1157-60.
5. Sherlock S: Chronic hepatitis and cirrhosis. *Hepatology* 1984;4:25S-28S.
6. Summerskill WH: Chronic active liver disease reexamined: prognosis hopeful. *Gastroenterology* 1974;66:450-64.

### 31. PBCによる肝硬変に対して UDCA を投与することで線維化の進展抑制効果が得られるか

1. Van Den Bogaert E, Francque S, Pelckmans P, Michielsen P: The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense. *Acta Gastroenterol Belg* 2003;66:283-7.
2. Talwalkar JA, Lindor KD: Primary biliary cirrhosis. *Lancet* 2003;362:53-61.
3. Bach N, Bodian C, Bodenheimer H, Croen E, Berk PD, Thung SN, Lindor KD, Therneau T, Schaffner F: Methotrexate therapy for primary biliary cirrhosis. *Am J Gastroenterol* 2003;98:187-93.
4. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. *Hepatology* 2002;36:525-31.
5. Ursodeoxycholic acid: a second look. Primary biliary cirrhosis: dashed hopes. *Prescribe Int* 2002;11:67-9.
6. Nishio A, Keeffe EB, Gershwin ME: Primary biliary cirrhosis: lessons learned from an organ-specific disease. *Clin Exp Med* 2001;1:165-78.
7. Angulo P: Use of ursodeoxycholic acid in patients with liver disease. *Curr Gastroenterol Rep* 2002;4:37-44.
8. Szalay F: Treatment of primary biliary cirrhosis. *J Physiol Paris* 2001;95:407-12.
9. Nishio A, Bass NM, Luketic VA, Coppel RL, Gershwin ME: Primary biliary cirrhosis: from induction to destruction. *Semin Gastrointest Dis* 2001;12:89-102.
10. Kumar D, Tandon RK: Use of ursodeoxycholic acid in liver diseases. *J Gastroenterol Hepatol* 2001;16:3-14.
11. Nishio A, Keeffe EB, Ishibashi H, Gershwin EM: Diagnosis and treatment of primary biliary cirrhosis. *Med Sci Monit* 2000;6:181-93.
12. Corpechot C, Carrat F, Bonnard AM, Poupon RE, Poupon R: The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. *Hepatology* 2000;32:1196-9.

13. Poupon R, Poupon RE: Treatment of primary biliary cirrhosis. *Baillieres Best Pract Res Clin Gastroenterol* 2000;14:615-28.
14. Kowdley KV: Ursodeoxycholic acid therapy in hepatobiliary disease. *Am J Med* 2000;108:481-6.
15. Trauner M, Graziadei IW: Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. *Aliment Pharmacol Ther* 1999;13:979-96.
16. Skulina D, Owczarek D, Cieccko-Michalska I, Szczepanski W, Tetnowski J, Garlicka M, Janas-Skulina U: [The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis] *Przegl Lek* 1999;56:201-4.
17. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R: Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. *Hepatology* 1999;29:1007-12.
18. Poupon RE, Huet PM, Poupon R, Bonnard AM, Nhieu JT, Zafrani ES: A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. *Hepatology* 1996;24:1098-103.
19. Poupon R, Poupon RE: Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. *Pharmacol Ther* 1995;66:1-15.
20. Cirillo NW, Zwas FR: Ursodeoxycholic acid in the treatment of chronic liver disease. *Am J Gastroenterol* 1994;89:1447-52.
21. Luketic VA, Sanyal AJ: The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. *Gastroenterologist* 1994;2:74-9.
22. Floreani A, Zappala F, Mazzetto M, Naccarato R, Plebani M, Chiaramonte M: Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. *Dig Dis Sci* 1994;39:9-14.
23. Matsuzaki Y, Doy M, Tanaka N, Shoda J, Osuga T, Nakano M, Aikawa T: Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. *J Clin Gastroenterol* 1994;18:36-41.
24. Kowdley KV, Kaplan MM: Treatment of primary biliary cirrhosis. *Gastroenterologist* 1993;1:199-210.
25. Arrese M, Accatino L: [Ursodeoxycholic acid in the treatment of cholestatic liver diseases] *Rev Med Chil* 1993;121:439-46.
26. Leuschner U: [Drug therapy of cholestatic hepatopathies] *Schweiz Rundsch Med Prax* 1992;81:983-4.
27. Shibata J, Fujiyama S, Honda Y, Sato T: Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. *J Gastroenterol Hepatol* 1992;7:277-82.
28. Poupon RE, Poupon R: Ursodeoxycholic acid for the treatment of cholestatic diseases. *Prog Liver Dis* 1992;10:219-38.
29. de Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC: Ursodeoxycholic acid in chronic liver disease. *Gut* 1991;32:1061-5.
30. Poupon RE, Balkau B, Eschwege E, Poupon R: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. *N Engl J Med* 1991;324:1548-54.
31. Poupon R: [Primary biliary cirrhosis] *Rev Prat* 1991;41:1161-5.
32. Stiehl A: [Therapy of cholestatic liver diseases with ursodeoxycholic acid: a new treatment principle] *Z Gastroenterol Verh* 1991;26:142-3.
33. Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M: Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. *Am J Gastroenterol* 1990;85:15-23.

### 食道静脈瘤の薬物療法

#### 3 2 . PPI 投与により肝硬変の消化管出血を予防できるか

1. Zhou Y, Qiao L, Wu J, Hu H, Xu C: Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a

controlled study. *J Gastroenterol Hepatol* 2002;17:973-9.

### 3 3 . H2ブロッカーの投与により肝硬変患者の消化管出血を予防できるか

1. Sokal EM, Van Hoorebeeck N, Van Obbergh L, Otte JB, Buts JP: Upper gastro-intestinal tract bleeding in cirrhotic children candidates for liver transplantation. *Eur J Pediatr* 1992;151:326-8.
2. Macdougall BR, Williams R: A controlled clinical trial of cimetidine in the recurrence of variceal hemorrhage: implications about the pathogenesis of hemorrhage. *Hepatology* 1983;3:69-73.

### 3 4 . $\beta$ -blocker は食道静脈瘤に対して有効な治療法となりうるか

1. Lo GH, Chen WC, Chen MH, Lin CP, Lo CC, Hsu PI, Cheng JS, Lai KH: Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. *Gastrointest Endosc* 2004;59:333-8.
2. Schiedermaier P, Koch L, Stoffel-Wagner B, Layer G, Sauerbruch T: Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. *Aliment Pharmacol Ther* 2003;18:777-84.
3. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S: Portal pressure response to losartan compared with propranolol in patients with cirrhosis. *Am J Gastroenterol* 2003;98:1371-6.
4. Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, Landeira G, Dominguez N, Romero G, Argonz J, Terg R: Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study. *Hepatology* 2003;37:359-65.
5. Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK: A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. *Gastroenterology* 2002;123:1013-9.
6. Silva G, Segovia R, Ponce R, Backhouse C, Palma M, Roblero JP, Abadal J, Quijada C, Troncoso M, Iturriaga H: Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis. *Hepatogastroenterology* 2002;49:1357-62.
7. Sauer P, Hansmann J, Richter GM, Stremmel W, Stiehl A: Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. *Endoscopy* 2002;34:690-7.
8. Escorsell A, Banares R, Garcia-Pagan JC, Gilabert R, Moitinho E, Piqueras B, Bru C, Echenagusia A, Granados A, Bosch J: TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. *Hepatology* 2002;35:385-92.
9. Avgerinos A, Armonis A, Manolakopoulos S, Rekoumis G, Argirakis G, Viazis N, Vlachogiannakos J, Adamopoulos A, Kanaghinis T, Raptis SA: Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial. *Gastrointest Endosc* 2000;51:652-8.
10. Cales P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, Bichard P, Raymond JM, Canva-Delcambre V, Vetter D, Valla D, Beauchant M, Hadengue A, Champigneulle B, Pascal JP, Poynard T, Lebrec D: Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. *Eur J Gastroenterol Hepatol* 1999;11:741-5.
11. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS: Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. *N Engl J Med* 1999;340:988-93.
12. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T: Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. *J Hepatol* 1997;26:312-24.
13. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T: Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. *Hepatology* 1997;25:63-70.

14. Tincani E, Cioni G, D'Alimonte P, Cristani A, Turrini F, Romagnoli R, Ventura E: Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. *Eur J Gastroenterol Hepatol* 1995;7:893-7.
15. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, Angeli P, Cavallarin G, Sebastianelli G, et al.: Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. *GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology* 1995;22:808-13.
16. Vickers C, Rhodes J, Chesner I, Hillenbrand P, Dawson J, Cockel R, Adams D, O'Connor H, Dykes P, Bradby H, et al.: Prevention of rebleeding from oesophageal varices: two-year follow up of a prospective controlled trial of propranolol in addition to sclerotherapy. *J Hepatol* 1994;21:81-7.
17. Feu F, Bordas JM, Luca A, Garcia-Pagan JC, Escorsell A, Bosch J, Rodes J: Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. *Hepatology* 1993;18:1082-9.
18. Kanazawa H, Watari A, Tada N, Matsusaka S, Nakatsuka K, Saitoh H, Yoshizawa M, Kuroda H, Kobayashi M, Nomura T: [Propranolol for prophylaxis of first hemorrhage in cirrhotic patients with esophageal varices--a controlled study comparing with sclerotherapy] *Nippon Shokakiby Gakkai Zasshi* 1993;90:2067-75.
19. Avgerinos A, Rekoumis G, Klonis C, Papadimitriou N, Gouma P, Pournaras S, Raptis S: Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial. *J Hepatol* 1993;19:301-11.
20. Acharya SK, Dasarathy S, Saksena S, Pande JN: A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. *J Hepatol* 1993;19:291-300.
21. Ink O, Martin T, Poynard T, Reville M, Anciaux ML, Lenoir C, Marill JL, Labadie H, Masliah C, Perrin D, et al.: Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. *Hepatology* 1992;16:912-9.
22. Dasarathy S, Dwivedi M, Bhargava DK, Sundaram KR, Ramachandran K: A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. *Hepatology* 1992;16:89-94.
23. Pagliaro L, D'Amico G, Sorensen TI, Lebec D, Burroughs AK, Morabito A, Tine F, Politi F, Traina M: Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. *Ann Intern Med* 1992;117:59-70.
24. Pagliaro L, D'Amico G, Tine F, Pasta L: Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment. *Dig Dis* 1992;10 Suppl 1:56-64.
25. Ricca Rosellini S, Miglio F: Beta-blockers for the prevention of variceal haemorrhage in patients with cirrhosis: an updated meta-analysis of randomized controlled trials. *Ital J Gastroenterol* 1991;23:408-15.
26. Kanazawa H, Watari A, Matsusaka S, Tada N, Miyata K, Saitoh H, Yoshizawa M, Kuroda H, Kobayashi M: [Prospective controlled study of elective sclerotherapy plus oral propranolol for prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage] *Nippon Shokakiby Gakkai Zasshi* 1991;88:1341-8.
27. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebec D: Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. *Franco-Italian Multicenter Study Group. N Engl J Med* 1991;324:1532-8.
28. Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodes J, Wright SC, Matloff DS, Garcia-Tsao G, Fisher RL, Navasa M, et al.: Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. *Hepatology* 1991;13:902-12.

29. Rossi V, Cales P, Burtin P, Charneau J, Person B, Pujol P, Valentin S, D'Aubigny N, Joubaud F, Boyer J: Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. *J Hepatol* 1991;12:283-9.
30. Andreani T, Poupon RE, Balkau BJ, Trinchet JC, Grange JD, Peigney N, Beaugrand M, Poupon R: Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. *Hepatology* 1990;12:1413-9.
31. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, et al.: Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. *Gastroenterology* 1990;99:1401-7.
32. Westaby D, Polson RJ, Gimson AE, Hayes PC, Hayllar K, Williams R: A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. *Hepatology* 1990;11:353-9.
33. Garden OJ, Mills PR, Birnie GG, Murray GD, Carter DC: Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. *Gastroenterology* 1990;98:185-90.
34. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. *J Hepatol* 1989;9:75-83.
35. Cales P, Grasset D, Ravaud A, Meskens C, Blanc M, Vinel JP, Cotonat J, Pascal JP: Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. *Br J Clin Pharmacol* 1989;27:763-70.
36. Kiire CF: Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. *BMJ* 1989;298:1363-5.
37. Cales P, Pierre-Nicolas M, Guell A, Mauroux JL, Franco-Sempe A, Vinel JP, Geraud G, Pascal JP: Propranolol does not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy. *Hepatology* 1989;9:439-42.
38. Colombo M, de Franchis R, Tommasini M, Sangiovanni A, Dioguardi N: Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. *Hepatology* 1989;9:433-8.
39. Sheen IS, Chen TY, Liaw YF: Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. *Liver* 1989;9:1-5.
40. Westaby D, Polson R, Gimson A, Hayes P, Williams R: Comparison of propranolol with injection sclerotherapy in prevention of rebleeding from oesophageal varices in cirrhotic patients. *Drugs* 1989;37 Suppl 2:42-6; discussion 47.
41. Pascal JP, Cales P: Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices. *Drugs* 1989;37 Suppl 2:52-61; discussion 74-6.
42. Pagliaro L, Pasta L, D'Amico G: A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding. *Drugs* 1989;37 Suppl 2:48-51; discussion 74-6.
43. Tommasini M, de Franchis R, Sangiovanni A, Colombo M: Beta-blockers in the secondary prevention of gastrointestinal haemorrhage in well-compensated cirrhotics. A multicentre randomised controlled study. *Drugs* 1989;37 Suppl 2:35-41; discussion 47.
44. Lebec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, Chaput JC, Rueff B, Benhamou JP: Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. *J Hepatol* 1988;7:118-25.
45. Ideo G, Bellati G, Fesce E, Grimoldi D: Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. *Hepatology* 1988;8:6-9.
46. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. *Hepatology* 1988;8:1-5.
47. Pascal JP, Cales P: Propranolol in the prevention of first upper gastrointestinal tract hemorrhage

- in patients with cirrhosis of the liver and esophageal varices. *N Engl J Med* 1987;317:856-61.
48. Fleig WE, Stange EF, Hunecke R, Schonborn W, Hurler U, Rainer K, Gaus W, Ditschuneit H: Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. *Hepatology* 1987;7:355-61.
  49. Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, Willems B, Huet PM, Marleau D, Viallet A: Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. *Hepatology* 1986;6:1239-43.
  50. Westaby D, Melia W, Hegarty J, Gimson AE, Stellon AJ, Williams R: Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. *Hepatology* 1986;6:673-5.
  51. Westaby D, Melia WM, Macdougall BR, Hegarty JE, Gimson AE, Williams R: B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis. *Gut* 1985;26:421-5.
  52. Burroughs AK, Jenkins WJ, Sherlock S, Dunk A, Walt RP, Osuafor TO, Mackie S, Dick R: Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. *N Engl J Med* 1983;309:1539-42.
  53. Lebrec D, Poynard T, Hillon P, Benhamou JP: Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. *N Engl J Med* 1981;305:1371-4.

### 3 5 . 食道胃静脈瘤に対し ARB、ACE 阻害剤は有効な治療法となるか

1. Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ: Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. *J Gastroenterol* 2003;38:1150-4.
2. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S: Portal pressure response to losartan compared with propranolol in patients with cirrhosis. *Am J Gastroenterol* 2003;98:1371-6.
3. Gonzalez-Abraldes J, Albillos A, Banares R, Del Arbol LR, Moitinho E, Rodriguez C, Gonzalez M, Escorsell A, Garcia-Pagan JC, Bosch J: Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. *Gastroenterology* 2001;121:382-8.

### 消化管出血、静脈瘤

#### 3 6 . RC sign は食道静脈瘤破裂の危険因子であるのか。

1. Park DK, Um SH, Lee JW, Lee JB, Kim YS, Park CH, Jin YT, Chun HJ, Lee HS, Lee SW, Choi JH, Kim CD, Ryu HS, Hyun JH: Clinical significance of variceal hemorrhage in recent years in patients with liver cirrhosis and esophageal varices. *J Gastroenterol Hepatol* 2004;19:1042-1051.
2. Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, Attili AF, Riggio O: Incidence and natural history of small esophageal varices in cirrhotic patients. *J Hepatol* 2003;38:266-72.
3. Murachima N, Ikeda K, Kobayashi M, Saitoh S, Chayama K, Tsubota A, Suzuki Y, Suzuki F, Arase Y, Kumada H: Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis. *J Gastroenterol* 2001;36:368-74.
4. Merkel C, Zoli M, Siringo S, van Buuren H, Magalotti D, Angeli P, Sacerdoti D, Bolondi L, Gatta A: Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. *Am J Gastroenterol* 2000;95:2915-20.
5. Craxi A, Camma C, Giunta M: Clinical aspects of bleeding complications in cirrhotic patients. *Blood Coagul Fibrinolysis* 2000;11 Suppl 1:S75-9.
6. Schiano TD, Adrain AL, Vega KJ, Liu JB, Black M, Miller LS: High-resolution endoluminal sonography assessment of the hematocystic spots of esophageal varices. *Gastrointest Endosc*

- 1999;49:424-7.
7. Hou MC, Lin HC, Kuo BI, Liao TM, Lee FY, Chang FY, Lee SD: Sequential variceal pressure measurement by endoscopic needle puncture during maintenance sclerotherapy: the correlation between variceal pressure and variceal rebleeding. *J Hepatol* 1998;29:772-8.
  8. Zoli M, Merkel C, Magalotti D, Marchesini G, Gatta A, Pisi E: Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. *Hepatology* 1996;24:1047-52.
  9. Colombo E, Casiraghi MA, Minoli G, Prada A, Terruzzi V, Bortoli A, Carnovali M, Gullotta R, Imperiali G, Comin U, et al.: First bleeding episode from oesophageal varices in cirrhotic patients: a prospective study of endoscopic predictive factors. *Ital J Gastroenterol* 1995;27:345-8.
  10. Siringo S, Bolondi L, Gaiani S, Sofia S, Zironi G, Rigamonti A, Di Febo G, Miglioli M, Cavalli G, Barbara L: Timing of the first variceal hemorrhage in cirrhotic patients: prospective evaluation of Doppler flowmetry, endoscopy and clinical parameters. *Hepatology* 1994;20:66-73.
  11. Kleber G, Sauerbruch T, Ansari H, Paumgartner G: Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. *Gastroenterology* 1991;100:1332-7.
  12. Cales P, Zabotto B, Meskens C, Caucanas JP, Vinel JP, Desmorat H, Fermanian J, Pascal JP: Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. *Gastroenterology* 1990;98:156-62.
  13. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. *N Engl J Med* 1988;319:983-9.

### 3 7 . 肝硬変患者において食道静脈瘤の screening を年 1 回の胃カメラを施行することで破裂のリスクは低下するか

1. Murachima N, Ikeda K, Kobayashi M, Saitoh S, Chayama K, Tsubota A, Suzuki Y, Suzuki F, Arase Y, Kumada H: Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis. *J Gastroenterol* 2001;36:368-74.
2. Cales P, Desmorat H, Vinel JP, Caucanas JP, Ravaud A, Gerin P, Brouet P, Pascal JP: Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. *Gut* 1990;31:1298-302.
3. Zaman A, Becker T, Lapidus J, Benner K: Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. *Arch Intern Med* 2001;161:2564-70.
4. Darwin P, Zangara J, Heller T, Haluszka O, Laurin J: Unsedated esophagoscopy for the diagnosis of esophageal varices in patients with cirrhosis. *Endoscopy* 2000;32:971-3.
5. Colombo E, Casiraghi MA, Minoli G, Prada A, Terruzzi V, Bortoli A, Carnovali M, Gullotta R, Imperiali G, Comin U, et al.: First bleeding episode from oesophageal varices in cirrhotic patients: a prospective study of endoscopic predictive factors. *Ital J Gastroenterol* 1995;27:345-8.
6. Snady H, Feinman L: Prediction of variceal hemorrhage: a prospective study. *Am J Gastroenterol* 1988;83:519-25.

### 3 8 . 食道静脈瘤に対する予防的 EVL および EIS は予後を改善するか

1. van Buuren HR, Rasch MC, Batenburg PL, Bolwerk CJ, Nicolai JJ, van der Werf SD, Scherpenisse J, Arends LR, van Hattum J, Rauws EA, Schalm SW: Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]. *BMC Gastroenterol* 2003;3:22.
2. Madonia S, D'Amico G, Traina M, Gatto G, Virdone R, Salamone N, Licata A, Tarantino I, Pagliaro L: Prognostic indicators of successful endoscopic sclerotherapy for prevention of rebleeding from oesophageal varices in cirrhosis: a long-term cohort study. *Dig Liver Dis* 2000;32:782-91.
3. Argonz J, Kravetz D, Suarez A, Romero G, Bildoizola M, Passamonti M, Valero J, Terg R: Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal



- bleeding in cirrhotic patients: a randomized, prospective and controlled trial. *Gastrointest Endosc* 2000;51:157-63.
4. Svoboda P, Kantorova I, Ochmann J, Kozumplik L, Marsova J: A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. *Surg Endosc* 1999;13:580-4.
  5. Svoboda P, Kantorova I, Ochmann J, Kozumplik L: Benefit of prophylactic endoscopic sclerotherapy of esophageal varices. A retrospective analysis. *Surg Endosc* 1998;12:835-8.
  6. Lay CS, Tsai YT, Teg CY, Shyu WS, Guo WS, Wu KL, Lo KJ: Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. *Hepatology* 1997;25:1346-50.
  7. Paquet KJ, Kalk JF, Klein CP, Gad HA: Prophylactic sclerotherapy for esophageal varices in high-risk cirrhotic patients selected by endoscopic and hemodynamic criteria: a randomized, single-center controlled trial. *Endoscopy* 1994;26:734-40.
  8. Koch H, Binmoeller KF, Grimm H, Soehendra N, Henning H, Oehler G: Prophylactic sclerotherapy for esophageal varices: long-term results of a prospective study. *Endoscopy* 1994;26:729-33.
  9. Potzi R, Bauer P, Schofl R, Reichel W, Kerstan E, Renner F, Gangl A: Prophylactic endoscopic sclerotherapy of esophageal varices in liver cirrhosis—long-term follow-up and final results of a multicenter prospective controlled randomized trial in Vienna. *Endoscopy* 1993;25:287-9.
  10. Triger DR, Smart HL, Hosking SW, Johnson AG: Prophylactic sclerotherapy for esophageal varices: long-term results of a single-center trial. *Hepatology* 1991;13:117-23.
  11. Kobe E, Zipprich B, Schentke KU, Nilius R: Prophylactic endoscopic sclerotherapy of esophageal varices—a prospective randomized trial. *Endoscopy* 1990;22:245-8.
  12. Potzi R, Bauer P, Reichel W, Kerstan E, Renner F, Gangl A: Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. A multicentre prospective controlled randomised trial in Vienna. *Gut* 1989;30:873-9.
  13. Piai G, Cipolletta L, Claar M, Marone G, Bianco MA, Forte G, Iodice G, Mattera D, Minieri M, Rocco P, et al.: Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial. *Hepatology* 1988;8:1495-500.
  14. Sauerbruch T, Wotzka R, Kopcke W, Harlin M, Heldwein W, Bayerdorffer E, Sander R, Ansari H, Starz I, Paumgartner G: Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. *N Engl J Med* 1988;319:8-15.
  15. Witzel L, Wolbergs E, Merki H: Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlled study. *Lancet* 1985;1:773-5.

### 39. 食道静脈瘤に対する予防的 EIS と EVL のどちらが再発が多いか

1. Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, Triantos C, Papaxoinis C, Manolakopoulos S, Panani A, Raptis SA: Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. *Hepatology* 2004;39:1623-30.
2. Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, Singh J, Rehman BU, Din Z: Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. *Hepatology* 2002;36:666-72.
3. Singh P, Pooran N, Indaram A, Bank S: Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. *Am J Gastroenterol* 2002;97:623-9.
4. Nevens F, Rutgeerts P: Variceal band ligation in the management of bleeding oesophageal varices: an overview. *Dig Liver Dis* 2001;33:284-7.
5. Cheng YS, Pan S, Lien GS, Suk FM, Wu MS, Chen JN, Chen SH: Adjuvant sclerotherapy after ligation for the treatment of esophageal varices: a prospective, randomized long-term study. *Gastrointest Endosc* 2001;53:566-71.
6. Hou MC, Lin HC, Lee FY, Chang FY, Lee SD: Recurrence of esophageal varices following endoscopic treatment and its impact on rebleeding: comparison of sclerotherapy and ligation. *J Hepatol* 2000;32:202-8.

7. Hou MC, Lin HC, Kuo BI, Lee FY, Chang FY, Lee SD: The rebleeding course and long-term outcome of esophageal variceal hemorrhage after ligation: comparison with sclerotherapy. *Scand J Gastroenterol* 1999;34:1071-6.
8. Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI, Chiang HT: Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. *J Hepatol* 1999;31:451-6.
9. Garg PK, Joshi YK, Tandon RK: Comparison of endoscopic variceal sclerotherapy with sequential endoscopic band ligation plus low-dose sclerotherapy for secondary prophylaxis of variceal hemorrhage: a prospective randomized study. *Gastrointest Endosc* 1999;50:369-73.
10. Masci E, Stigliano R, Mariani A, Bertoni G, Baroncini D, Cennamo V, Micheletti G, Casetti T, Tansini P, Buscarini E, Ranzato R, Norberto L: Prospective multicenter randomized trial comparing banding ligation with sclerotherapy of esophageal varices. *Hepatogastroenterology* 1999;46:1769-73.
11. Svoboda P, Kantorova I, Ochmann J, Kozumplik L, Marsova J: A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. *Surg Endosc* 1999;13:580-4.
12. Tait IS, Krige JE, Terblanche J: Endoscopic band ligation of oesophageal varices. *Br J Surg* 1999;86:437-46.
13. de la Pena J, Rivero M, Sanchez E, Fabrega E, Crespo J, Pons-Romero F: Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. *Gastrointest Endosc* 1999;49:417-23.
14. Gotoh Y, Iwakiri R, Sakata Y, Koyama T, Noda T, Matsunaga C, Ogata SI, Ishibashi S, Sakata H, Tsunada S, Fujimoto K: Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices: a prospective, controlled trial compared with endoscopic injection sclerotherapy. *J Gastroenterol Hepatol* 1999;14:241-4.
15. Grace ND: Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. *Am J Gastroenterol* 1997;92:1081-91.
16. Baroncini D, Milandri GL, Borioni D, Piemontese A, Cennamo V, Billi P, Dal Monte PP, D'Imperio N: A prospective randomized trial of sclerotherapy versus ligation in the elective treatment of bleeding esophageal varices. *Endoscopy* 1997;29:235-40.
17. Avgerinos A, Armonis A, Manolakopoulos S, Poulianos G, Rekoumis G, Sgourou A, Gouma P, Raptis S: Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study. *J Hepatol* 1997;26:1034-41.
18. Lo GH, Lai KH, Cheng JS, Lin CK, Huang JS, Hsu PI, Chiang HT: Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. *Hepatology* 1997;25:1101-4.
19. Sarin SK, Govil A, Jain AK, Guptan RC, Issar SK, Jain M, Murthy NS: Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. *J Hepatol* 1997;26:826-32.
20. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. *Ann Intern Med* 1995;123:280-7.
21. Lo GH, Lai KH, Cheng JS, Hwu JH, Chang CF, Chen SM, Chiang HT: A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. *Hepatology* 1995;22:466-71.
22. Hou MC, Lin HC, Kuo BI, Chen CH, Lee FY, Lee SD: Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. *Hepatology* 1995;21:1517-22.
23. Gimson AE, Ramage JK, Panos MZ, Hayllar K, Harrison PM, Williams R, Westaby D: Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. *Lancet* 1993;342:391-4.
24. Laine L, el-Newihi HM, Migikovsky B, Sloane R, Garcia F: Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. *Ann Intern Med* 1993;119:1-7.
25. Hashizume M, Ohta M, Ueno K, Tanoue K, Kitano S, Sugimachi K: Endoscopic ligation of

esophageal varices compared with injection sclerotherapy: a prospective randomized trial. *Gastrointest Endosc* 1993;39:123-6.

#### 4 0 . 食道静脈瘤破裂時にバゾプレシンあるいはサンドスタチン、一硝酸イソソルバイドといった薬物療法は有効か

1. de Franchis R: Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. *Dig Liver Dis* 2004;36 Suppl 1:S93-100.
2. Lee HY, Lee HJ, Lee SM, Kim JH, Kweon SW, Lee BS, Kim NJ: A prospective randomized controlled clinical trial comparing the effects of somatostatin and vasopressin for control of acute variceal bleeding in the patients with liver cirrhosis. *Korean J Intern Med* 2003;18:161-6.
3. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. *Gastroenterology* 2003;124:1277-91.
4. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. *Cochrane Database Syst Rev* 2003;:CD002147.
5. Ioannou GN, Doust J, Rockey DC: Systematic review: terlipressin in acute oesophageal variceal haemorrhage. *Aliment Pharmacol Ther* 2003;17:53-64.
6. Zhang HB, Wong BC, Zhou XM, Guo XG, Zhao SJ, Wang JH, Wu KC, Ding J, Lam SK, Fan DM: Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding. *Int J Clin Pract* 2002;56:447-51.
7. Lin HC, Yang YY, Hou MC, Huang YT, Lee WC, Lee FY, Chang FY, Lee SD: Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. *Scand J Gastroenterol* 2002;37:482-7.
8. D'Amico G: First meta-analysis of octreotide for variceal bleeding. A lost opportunity. *J Hepatol* 2002;36:574-7.
9. Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, Salcedo M, Molinero LM: Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. *Hepatology* 2002;35:609-15.
10. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L: Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. *Cochrane Database Syst Rev* 2002;:CD002233.
11. Gotzsche PC: Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2002;:CD000193.
12. Gross M, Schiemann U, Muhlhofer A, Zoller WG: Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding. *Endoscopy* 2001;33:737-46.
13. Wong T, Wilkinson ML: Somatostatin plus isosorbide mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled trial. *Gastrointest Endosc* 2001;54:275-6; discussion 275-6.
14. Erstad BL: Octreotide for acute variceal bleeding. *Ann Pharmacother* 2001;35:618-26.
15. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. *Cochrane Database Syst Rev* 2001;:CD002147.
16. Freitas DS, Sofia C, Pontes JM, Gregorio C, Cabral JP, Andrade P, Rosa A, Camacho E, Ferreira M, Portela F, Romaozinho JM, Tome L, Gouveia H, Leitao M, Pimenta I, Donato A: Octreotide in acute bleeding esophageal varices: a prospective randomized study. *Hepatogastroenterology* 2000;47:1310-4.
17. Bildozola M, Kravetz D, Argonz J, Romero G, Suarez A, Jmelnitzky A, Fainberg M, Fassio E, Berreta J, Romero G, Landeira G, Martinez H, Bosco A, Guevara M, Valero J, Chopita N, Berenstein G, Terg R: Efficacy of octreotide and sclerotherapy in the treatment of acute variceal bleeding in cirrhotic patients. A prospective, multicentric, and randomized clinical trial. *Scand J Gastroenterol* 2000;35:419-25.
18. Gotzsche PC: Somatostatin or octreotide for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2000;:CD000193.
19. Zuberi BF, Baloch Q: Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with

- low-risk cirrhosis. *Am J Gastroenterol* 2000;95:768-71.
20. Sivri B, Oksuzoglu G, Bayraktar Y, Kayhan B: A prospective randomized trial from Turkey comparing octreotide versus injection sclerotherapy in acute variceal bleeding. *Hepatogastroenterology* 2000;47:168-73.
  21. D'Amico G, Pagliaro L, Bosch J: Pharmacological treatment of portal hypertension: an evidence-based approach. *Semin Liver Dis* 1999;19:475-505.
  22. Junquera F, Lopez-Talavera JC, Mearin F, Saperas E, Videla S, Armengol JR, Esteban R, Malagelada JR: Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial. *Gut* 2000;46:127-32.
  23. Lee JG: A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of variceal haemorrhage. *Gastrointest Endosc* 1998;48:442-4.
  24. Sheikh RA, Trudeau WL: Randomised trial of octreotide for long term management of cirrhosis after variceal hemorrhage. *Gastrointest Endosc* 1998;48:328-30.
  25. Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, Grime JS, Love JG, Sutton R: Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. *BMJ* 1997;315:1338-41.
  26. Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R: A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. *Gut* 1997;41:526-33.
  27. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L: Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. *Gastroenterology* 1997;113:1632-9.
  28. Imperiale TF, Teran JC, McCullough AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. *Gastroenterology* 1995;109:1289-94.
  29. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, Larricq J, Gourlaouen A, Ribard D, et al.: Sclerotherapy with or without octreotide for acute variceal bleeding. *N Engl J Med* 1995;333:555-60.
  30. Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F: Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
  31. Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, Staudacher C, Beretta L, Motta R, de Franchis R: Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. *New Italian Endoscopic Club. Hepatology* 1995;21:1322-7.
  32. Avgerinos A, Armonis A, Raptis S: Somatostatin and octreotide in the management of acute variceal hemorrhage. *Hepatogastroenterology* 1995;42:145-50.
  33. Orloff MJ, Bell RH Jr, Orloff MS, Hardison WG, Greenburg AG: Prospective randomized trial of emergency portacaval shunt and emergency medical therapy in unselected cirrhotic patients with bleeding varices. *Hepatology* 1994;20:863-72.
  34. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F: Octreotide versus terlipressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. *Clin Investig* 1994;72:653-9.
  35. D'Amico G, Traina M, Vizzini G, Tine F, Politi F, Montalbano L, Luca A, Pasta L, Pagliaro L, Morabito A: Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. *Liver Study Group of V. Cervello Hospital. J Hepatol* 1994;20:206-12.
  36. De Franchis R: Treatment of bleeding oesophageal varices: a meta-analysis. *Scand J Gastroenterol Suppl* 1994;207:29-33.
  37. de Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, Zambelli A, Battaglia G, Mannucci PM: Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. *New Italian Endoscopic Club. Hepatology* 1993;18:1102-7.
  38. Sung JJ, Chung SC, Lai CW, Chan FK, Leung JW, Yung MY, Kassianides C, Li AK: Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. *Lancet* 1993;342:637-41.

39. Silvain C, Carpentier S, Sautereau D, Czernichow B, Metreau JM, Fort E, Ingrand P, Boyer J, Pillegard B, Doffel M, et al.: Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. *Hepatology* 1993;18:61-5.
40. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, Wang SS, Lee SD, Tsai YT, Lo KJ: A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. *J Hepatol* 1992;16:320-5.
41. Huang CC, Sheen IS, Chu CM, Chuah SK, Chien RN, Peng SM, Kuo YC, Lin SM, Lin DY, Chen PC, et al.: A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. *Changeng Yi Xue Za Zhi* 1992;15:78-83.
42. Chiu KW, Sheen IS, Liaw YF: A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices. *J Gastroenterol Hepatol* 1990;5:549-53.
43. Saari A, Klvilaakso E, Inberg M, Paakkonen M, Lahtinen J, Hockerstedt K, Schroder T: Comparison of somatostatin and vasopressin in bleeding esophageal varices. *Am J Gastroenterol* 1990;85:804-7.
44. Soderlund C, Magnusson I, Tomgren S, Lundell L: Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. *Scand J Gastroenterol* 1990;25:622-30.
45. Teres J, Planas R, Panes J, Salmeron JM, Mas A, Bosch J, Llorente C, Viver J, Feu F, Rodes J: Vasopressin/nitroglycerin infusion vs. esophageal tamponade in the treatment of acute variceal bleeding: a randomized controlled trial. *Hepatology* 1990;11:964-8.
46. Bosch J, Groszmann RJ, Garcia-Pagan JC, Teres J, Garcia-Tsao G, Navasa M, Mas A, Rodes J: Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. *Hepatology* 1989;10:962-8.
47. Westaby D, Hayes PC, Gimson AE, Polson RJ, Williams R: Controlled clinical trial of injection sclerotherapy for active variceal bleeding. *Hepatology* 1989;9:274-7.
48. el-Zayadi A, el-Din SS, Kabil SM: Endoscopic sclerotherapy versus medical treatment for bleeding esophageal varices in patients with schistosomal liver disease. *Gastrointest Endosc* 1988;34:314-7.
49. Soderlund C: Long-term survivors after variceal haemorrhage. Follow-up of a controlled study of endoscopic sclerotherapy versus conservative management. *Scand J Gastroenterol* 1987;22:665-71.
50. Gimson AE, Westaby D, Hegarty J, Watson A, Williams R: A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. *Hepatology* 1986;6:410-3.
51. Tsai YT, Lay CS, Lai KH, Ng WW, Yeh YS, Wang JY, Chiang TT, Lee SD, Chiang BN, Lo KJ: Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. *Hepatology* 1986;6:406-9.
52. Walker S, Stiehl A, Raedsch R, Kommerell B: Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. *Hepatology* 1986;6:112-5.
53. Jenkins SA, Baxter JN, Corbett W, Devitt P, Ware J, Shields R: A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. *Br Med J (Clin Res Ed)* 1985;290:275-8.
54. Pinto Correia J, Martins Alves M, Alexandrino P, Silveira J: Controlled trial of vasopressin and balloon tamponade in bleeding esophageal varices. *Hepatology* 1984;4:885-8.
55. Kravetz D, Bosch J, Teres J, Bruix J, Rimola A, Rodes J: Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. *Hepatology* 1984;4:442-6.
56. Freeman JG, Cobden I, Lishman AH, Record CO: Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. *Lancet* 1982;2:66-8.
57. Mallory A, Schaefer JW, Cohen JR, Holt SA, Norton LW: Selective intra-arterial vasopressin infusion for upper gastrointestinal tract hemorrhage: a controlled trial. *Arch Surg* 1980;115:30-2.
58. Chojkier M, Groszmann RJ, Atterbury CE, Bar-Meir S, Blei AT, Frankel J, Glickman MG, Kniaz JL, Schade R, Taggart GJ, Conn HO: A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. *Gastroenterology* 1979;77:540-6.

59. Johnson WC, Widrich WC, Ansell JE, Robbins AH, Nabseth DC: Control of bleeding varices by vasopressin: a prospective randomized study. *Ann Surg* 1977;186:369-76.
60. Conn HO, Ramsby GR, Storer EH, Mutchnick MG, Joshi PH, Phillips MM, Cohen GA, Fields GN, Petroski D: Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. *Gastroenterology* 1975;68:211-21.

#### 4 1 . 食道静脈瘤破裂に対し Hasaab 手術は有効か

1. Gacyk W, Zadrozny D, Draczkowski T, Kostro J: [Prospective evaluation of treatment results while using surgical esophageal devascularization and transection for esophageal varices] *Wiad Lek* 1997;50 Suppl 1 Pt 1:308-12.
2. Borgonovo G, Costantini M, Grange D, Vons C, Smadja C, Franco D: Comparison of a modified Sugiura procedure with portal systemic shunt for prevention of recurrent variceal bleeding in cirrhosis. *Surgery* 1996;119:214-21.
3. Mariette D, Smadja C, Borgonovo G, Grange D, Franco D: The Sugiura procedure: a prospective experience. *Surgery* 1994;115:282-9. ID:8128352

#### 4 2 . 食道静脈瘤破裂の治療として経皮経肝門脈塞栓術は有効か

1. Terabayashi H, Ohnishi K, Tsunoda T, Nakata H, Saito M, Tanaka H, Iida S, Nomura F, Okuda K: Prospective controlled trial of elective endoscopic sclerotherapy in comparison with percutaneous transhepatic obliteration of esophageal varices in patients with nonalcoholic cirrhosis. *Gastroenterology* 1987;93:1205-9.
2. Ohnishi K, Takayasu K, Takashi M, Suzuki N, Hirashima T, Hara T, Saito M, Hatano H, Nakayama T, Nomura F, et al.: Transhepatic obliteration of esophageal varices using stainless coils combined with hypertonic glucose and gelfoam. *J Clin Gastroenterol* 1985;7:200-7.
3. Smith-Laing G, Scott J, Long RG, Dick R, Sherlock S: Role of percutaneous transhepatic obliteration of varices in the management of hemorrhage from gastroesophageal varices. *Gastroenterology* 1981;80:1031-6. ID:7009311

#### 4 3 . 胃静脈瘤破裂の予防としてバルーン下逆行性経静脈的静脈瘤塞栓術(B-RTO)は有効か

1. Shiba M, Higuchi K, Nakamura K, Itani A, Kuga T, Okazaki H, Fujiwara Y, Arakawa T: Efficacy and safety of balloon-occluded endoscopic injection sclerotherapy as a prophylactic treatment for high-risk gastric fundal varices: a prospective, randomized, comparative clinical trial. *Gastrointest Endosc* 2002;56:522-8.
2. Kitamoto M, Imamura M, Kamada K, Aikata H, Kawakami Y, Matsumoto A, Kurihara Y, Kono H, Shirakawa H, Nakanishi T, Ito K, Chayama K: Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage. *AJR Am J Roentgenol* 2002;178:1167-74.
3. Hirota S, Matsumoto S, Tomita M, Sako M, Kono M: Retrograde transvenous obliteration of gastric varices. *Radiology* 1999;211:349-56.
4. Terabayashi H, Ohnishi K, Tsunoda T, Nakata H, Saito M, Tanaka H, Iida S, Nomura F, Okuda K: Prospective controlled trial of elective endoscopic sclerotherapy in comparison with percutaneous transhepatic obliteration of esophageal varices in patients with nonalcoholic cirrhosis. *Gastroenterology* 1987;93:1205-9.

#### 4 4 . 食道静脈瘤治療後の患者の内視鏡検査の頻度は1年ごとに行うことで破裂のリスクを低下させることが出来るか

1. Colombo E, Casiraghi MA, Minoli G, Prada A, Terruzzi V, Bortoli A, Carnovali M, Gullotta R, Imperiali G, Comin U, et al.: First bleeding episode from oesophageal varices in cirrhotic patients: a prospective study of endoscopic predictive factors. *Ital J Gastroenterol* 1995;27:345-8.

#### 4 5 . 食道静脈瘤破裂時の第 1 選択の治療として EVL、EIS は SB tube 挿入に比較し有効か

1. Lo GH, Lai KH, Ng WW, Tam TN, Lee SD, Tsai YT, Lo KJ: Injection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: a prospective randomized trial. *Gastrointest Endosc* 1992;38:421-4.
2. Paquet KJ, Feussner H: Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective controlled randomized trial. *Hepatology* 1985;5:580-3.

#### 腹水

#### 4 6 . 腹水のコントロールは肝硬変の予後を改善するか

1. Garcia-Compean D, Blanc P, Larrey D, Daures JP, Hirtz J, Mendoza E, Maldonado H, Michel H: Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. *Ann Hepatol* 2002;1:29-35.
2. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Peron JM, Abralles JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP: Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. *Gastroenterology* 2004;126:469-75.
3. Nidegger D, Ragot S, Berthelemy P, Masliah C, Pilette C, Martin T, Bianchi A, Paupard T, Silvain C, Beauchant M: Cirrhosis and bleeding: the need for very early management. *J Hepatol* 2003;39:509-14.
4. Santos J, Planas R, Pardo A, Durandez R, Cabre E, Morillas RM, Granada ML, Jimenez JA, Quintero E, Gassull MA: Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. *J Hepatol* 2003;39:187-92.
5. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, Rodriguez J, Such J, Pascual S, Soriano G, Perez-Mateo M, Guarner C: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. *Hepatology* 2003;37:1147-53.
6. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. *Gastroenterology* 2003;124:933-9.
7. Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, Landeira G, Dominguez N, Romero G, Argonz J, Terg R: Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study. *Hepatology* 2003;37:359-65.
8. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. *Hepatology* 2003;37:182-91.
9. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. *Gastroenterology* 2002;123:1839-47.
10. Pamuk ON, Sonsuz A: The effect of mannitol infusion on the response to diuretic therapy in cirrhotic patients with ascites. *J Clin Gastroenterol* 2002;35:403-5.
11. Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, Visentin S, Panzeri A, de Franchis R: Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. *J Hepatol* 2002;37:315-21.
12. Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, Santos PM, Alves MM, Moura MC: Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. *Eur J Gastroenterol Hepatol* 2002;14:377-81.
13. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grange JD, Valla D, Lebrec D: Comparison of the effect of terlipressin and albumin on arterial

- blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. *Gut* 2002;50:90-4.
14. Garcia-Pagan JC, Villanueva C, Vila MC, Albillos A, Genesca J, Ruiz-Del-Arbol L, Planas R, Rodriguez M, Calleja JL, Gonzalez A, Sola R, Balanzo J, Bosch J: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. *Gastroenterology* 2001;121:908-14.
  15. Abecasis R, Guevara M, Miguez C, Cobas S, Terg R: Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. *Scand J Gastroenterol* 2001;36:309-13.
  16. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000;342:1701-7.
  17. Li CP, Lee FY, Hwang SJ, Chang FY, Lin HC, Kuo BI, Chu CJ, Lee SD: Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. *Am J Gastroenterol* 2000;95:1051-5.
  18. Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Bolognesi M, Felder M, Mazzaro C, Gatta A: Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. *Hepatology* 2000;31:324-9.
  19. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegno L, Merkel C, Gatta A, Alberti A: Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. *Hepatogastroenterology* 1999;46:3216-22.
  20. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol* 1999;30:639-45.
  21. Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, Dickson ER, Lindor KD: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. *Hepatology* 1999;29:21-6.
  22. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, Richardet JP, Vinel JP, Delisle F, Fischer D, Flahault A, Amiot X: Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. *J Hepatol* 1998;29:430-6.
  23. Stanley AJ, Forrest EH, Dabos KJ, MacGilchrist AJ, Hayes PC: Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study. *Aliment Pharmacol Ther* 1998;12:389-93.
  24. Rastegar LA, Umrani G, Dehbashi N, Malec F: Evaluation of the therapeutic effect of pefloxacin in comparison with ampicillin and gentamicin in cirrhotic patients with spontaneous bacterial peritonitis. *Hepatogastroenterology* 1998;45:783-5.
  25. Adhami JE, Basho J: Treatment with colchicine and survival of patients with ascitic cirrhosis: a double-blind randomized trial. *Panminerva Med* 1998;40:75-81.
  26. Altman C, Bernard B, Roulot D, Vitte RL, Ink O: Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. *Eur J Gastroenterol Hepatol* 1998;10:5-10.
  27. Graziotto A, Rossaro L, Inturri P, Salvagnini M: Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. *Dig Dis Sci* 1997;42:1708-14.
  28. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, Planas R, Lebec D, Geuvel A, Elewaut A, Adler M, Arroyo V: Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. *J Hepatol* 1997;26:614-20.
  29. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, Sabat M, Vila MC, Guarner C, Vilardell F: Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. *Hepatology* 1997;25:532-6.
  30. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J: Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis.



Gastroenterology 1996;111:1002-10.

31. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S: Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. *J Hepatol* 1996;25:135-44.
32. Gines A, Planas R, Angeli P, Guarner C, Salerno F, Gines P, Salo J, Rodriguez N, Domenech E, Soriano G, et al.: Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. *Hepatology* 1995;22:124-31.
33. Singh N, Gayowski T, Yu VL, Wagener MM: Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. *Ann Intern Med* 1995;122:595-8.
34. Poupon RE, Poupon R, Balkau B: Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. *N Engl J Med* 1994;330:1342-7.
35. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. *Gastroenterology* 1994;106:1284-90.
36. Sola R, Vila MC, Andreu M, Oliver MI, Coll S, Gana J, Ledesma S, Gines P, Jimenez W, Arroyo V: Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. *J Hepatol* 1994;20:282-8.
37. Christensen E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R: Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. *Gastroenterology* 1993;105:1865-76.
38. Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, Podesta A, Rodriguez P, Levi D, Kravetz D: Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. *J Hepatol* 1992;14:310-6.
39. Hagege H, Ink O, Ducreux M, Pelletier G, Buffet C, Etienne JP: [Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin] *Gastroenterol Clin Biol* 1992;16:751-5.
40. Pagliaro L, D'Amico G, Tine F, Pasta L: Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment. *Dig Dis* 1992;10 Suppl 1:56-64.
41. Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, Hoyos M, Viladomiu L, Rimola A, Morillas R, et al.: Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 1991;325:829-35.
42. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D: Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. *N Engl J Med* 1991;324:1532-8.
43. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P: Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. *Hepatology* 1991;13:707-13.
44. Triger DR, Smart HL, Hosking SW, Johnson AG: Prophylactic sclerotherapy for esophageal varices: long-term results of a single-center trial. *Hepatology* 1991;13:117-23.
45. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, Salmeron JM, Gines A, Toledo C, Rimola A, et al.: Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. *Gastroenterology* 1990;99:1736-44.
46. Chesta J, Brahm J, Latorre R, Gidi J, Hurtado C, Antezana C, Novoa X, Velasco M: [Paracentesis combined with albumin infusion in the treatment of tense ascites in cirrhotic patients] *Rev Med Chil* 1990;118:874-80.
47. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, Allen MJ, Baum RA, Gadacz TR, Camara DS: Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. *N Engl J Med* 1989;321:1632-8.
48. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of

- a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. *J Hepatol* 1989;9:75-83.
49. Pagliaro L, Pasta L, D'Amico G: A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding. *Drugs* 1989;37 Suppl 2:48-51; discussion 74-6.
  50. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, Torres M, Humbert P, Rimola A, Llach J, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. *Gastroenterology* 1988;94:1493-502.
  51. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. *Hepatology* 1988;8:1-5.
  52. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, Viver J, Camps J, Jimenez W, et al.: Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. *Gastroenterology* 1987;93:234-41.
  53. Gatta A, Merkel C, Sacerdoti D, Bolognesi M, Caregaro L, Zuin R, Angeli P, Ruol A: Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. *Digestion* 1987;37:22-8.
  54. Gauthier A, Levy VG, Quinton A, Michel H, Rueff B, Descos L, Durbec JP, Fermanian J, Lancrenon S: Salt or no salt in the treatment of cirrhotic ascites: a randomised study. *Gut* 1986;27:705-9.
  55. Fulenwider JT, Galambos JD, Smith RB 3rd, Henderson JM, Warren WD: LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized, prospective trial. *Arch Surg* 1986;121:351-5.
  56. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. *N Engl J Med* 1984;311:1594-600.
  57. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N: Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. *Hepatology* 1984;4:430-5.
  58. Lebec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP, Poupon R, Bouvry M, Rueff B, Benhamou JP: A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. *Hepatology* 1984;4:355-8.
  59. Schlichting P, Christensen E, Fauerholdt L, Poulsen H, Juhl E, Tygstrup N: Prednisone and chronic liver disease. II. Clinical versus morphological criteria for selection of patients for prednisone treatment. *Liver* 1982;2:113-8.
  60. Schlichting P, Fauerholdt L, Christensen E, Poulsen H, Juhl E, Tygstrup N: Prednisone treatment of chronic liver disease. I. Chronic aggressive hepatitis as a therapeutic marker. *Liver* 1982;2:104-12. ID:7176839

#### 4 7 . 肝硬変に伴う腹水に対して減塩食は有効か

1. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, Rodriguez J, Such J, Pascual S, Soriano G, Perez-Mateo M, Guamer C: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. *Hepatology* 2003;37:1147-53.
2. Degoricija V, Zjadic-Rotkvic V, Marout J, Sefer S, Troskot B: Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial. *Croat Med J* 2003;44:178-86.
3. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. *Gastroenterology* 2003;124:933-9.
4. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. *Hepatology* 2003;37:182-91.
5. Pamuk ON, Sonsuz A: The effect of mannitol infusion on the response to diuretic therapy in

- cirrhotic patients with ascites. *J Clin Gastroenterol* 2002;35:403-5.
6. Zaak D, Paquet KJ, Kuhn R: Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. *Z Gastroenterol* 2001;39:5-10.
  7. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol* 1999;30:639-45.
  8. Stanley AJ, Forrest EH, Dabos KJ, MacGilchrist AJ, Hayes PC: Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study. *Aliment Pharmacol Ther* 1998;12:389-93.
  9. Gadano A, Moreau R, Vachier F, Soupison T, Yang S, Cailmail S, Sogni P, Hadengue A, Durand F, Valla D, Lebrec D: Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. *J Hepatol* 1997;26:1229-34.
  10. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, Planas R, Lebrec D, Geuvel A, Elewaut A, Adler M, Arroyo V: Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. *J Hepatol* 1997;26:614-20.
  11. Gentilini P, La Villa G, Marra F, Carloni V, Melani L, Foschi M, Cotrozzi G, Quartini M, Chibbaro G, Tommasi AC, Bernareggi A, Simoni A, Buzzelli G, Laffi G: Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. *J Hepatol* 1996;25:481-90.
  12. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J: Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. *Gastroenterology* 1996;111:1002-10.
  13. Tsai YT, Lin HC, Lee FY, Hou MC, Wang SS, Lee SD: Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis. *Proc Natl Sci Counc Repub China B* 1996;20:44-50.
  14. Hsia HC, Lin HC, Tsai YT, Lee FY, Hwang CC, Hou MC, Lee SD: The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. *Scand J Gastroenterol* 1995;30:1194-9.
  15. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, Angeli P, Cavallarin G, Sebastianelli G, et al.: Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. *GTIP Gruppo Triveneto per l'Iipertensione Portale. Hepatology* 1995;22:808-13.
  16. Luca A, Garcia-Pagan JC, Bosch J, Feu F, Jimenez W, Gines A, Fernandez M, Escorsell A, Arroyo V, Rodes J: Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. *Hepatology* 1995;22:753-8.
  17. Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, Ceolotto G, Gatta A: Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. *Hepatology* 1994;19:72-9.
  18. Knauf H, Mutschler E: Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide. *Cardiology* 1994;84 Suppl 2:87-98.
  19. Gerbes AL, Bertheau-Reitha U, Falkner C, Jungst D, Paumgartner G: Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. *J Hepatol* 1993;17:353-8.
  20. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Casini Raggi V, Foschi M, Marra F, Pinzani M, et al.: Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. *Gastroenterology* 1993;104:588-94.
  21. Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F: Torasemide in the treatment of patients with cirrhosis and ascites. *Cardiovasc Drugs Ther* 1993;7 Suppl 1:81-5.
  22. Laffi G, Marra F, Carloni V, Azzena G, De Feo ML, Pinzani M, Tosti-Guerra C, Gentilini P: Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. *Gastroenterology* 1992;103:1017-21.

23. Lai KN, Li P, Law E, Swaminathan R, Nicholls MG: Large-volume paracentesis versus dialytic ultrafiltration in the treatment of cirrhotic ascites. *Q J Med* 1991;78:33-41.
24. Knauf H, Wenk E, Scholmerich J, Goerg KJ, Gerok W, Leser HG, Mutschler E: Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion. *Klin Wochenschr* 1990;68:545-51.
25. Wilken-Jensen C, Ring-Larsen H, Henriksen JH, Clausen J, Pals H, Christensen NJ: [Effect of posture on the diuretic treatment of decompensated cirrhosis and heart failure] *Ugeskr Laeger* 1989;151:13-5.
26. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, Torres M, Humbert P, Rimola A, Llach J, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. *Gastroenterology* 1988;94:1493-502.
27. Brunner G, von Bergmann K, Hacker W, von Mollendorff E: Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydroppically decompensated cirrhosis of the liver. *Arzneimittelforschung* 1988;38:176-9.
28. Sarin SK, Sachdev G, Mishra SP, Sundaram KR, Shrivastwa A, Talukdar V, Broor SL: Bumetanide, spironolactone and a combination of the two, in the treatment of ascites due to liver disease. A prospective, controlled, randomized trial. *Digestion* 1988;41:101-7.
29. Nicholls KM, Shapiro MD, Groves BS, Schrier RW: Factors determining renal response to water immersion in non-excretor cirrhotic patients. *Kidney Int* 1986;30:417-21.
30. Gauthier A, Levy VG, Quinton A, Michel H, Rueff B, Descos L, Durbec JP, Fermanian J, Lancrenon S: Salt or no salt in the treatment of cirrhotic ascites: a randomised study. *Gut* 1986;27:705-9.
31. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ: Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. *Br Med J (Clin Res Ed)* 1986;292:1351-3.
32. D'Arienzo A, Ambrogio G, Di Siervi P, Perna E, Squame G, Mazzacca G: A randomized comparison of metoclopramide and domperidone on plasma aldosterone concentration and on spironolactone-induced diuresis in ascitic cirrhotic patients. *Hepatology* 1985;5:854-7.
33. Bernardi M, De Palma R, Trevisani F, Santini C, Servadei D, Gasbarrini G: Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis. *Z Kardiol* 1985;74 Suppl 2:129-34.
34. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N: Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. *Hepatology* 1984;4:430-5.
35. Perez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodes J: Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. *Gastroenterology* 1983;84:961-8.
36. Descos L, Gauthier A, Levy VG, Michel H, Quinton A, Rueff B, Fermanian J, Fombonne E, Durbec JP: Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. *Hepatogastroenterology* 1983;30:15-20.
37. Nasrallah SM, Galambos JT: Aminoacid therapy of alcoholic hepatitis. *Lancet* 1980;2:1276-7.
38. Wapnick S, Grosberg SJ, Evans MI: Randomized prospective matched pair study comparing peritoneovenous shunt and conventional therapy in massive ascites. *Br J Surg* 1979;66:667-70.
39. Reynolds TB, Lieberman FL, Goodman AR: Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. *Gut* 1978;19:549-53.

#### 4 8 . 肝硬変に伴う腹水にループス利尿薬は有用か

1. Santos J, Planas R, Pardo A, Durandez R, Cabre E, Morillas RM, Granada ML, Jimenez JA, Quintero E, Gassull MA: Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. *J Hepatol* 2003;39:187-92.
2. Degoricija V, Zjacic-Rotkovic V, Marout J, Sefer S, Troskot B: Clinical and neurohumoral response